Emcure Pharmaceuticals
Emcure delivered a strong Q4 FY26 with revenue of ₹2,470 crore (+16.7% YoY) and EBITDA margin expansion of 130 bps to 19.7%, driven by robust international growth (+25.7%) and operating leverage.
Emcure Pharmaceuticals vs Ajanta Pharma Q4 FY26
Side-by-side earnings comparison across verified financials, sentiment, risks, and management commentary.
Ajanta Pharma
Ajanta Pharma delivered a strong Q4 FY26 with revenue of ₹1,422 crore (+21% YoY) and PAT of ₹267 crore (+18% YoY).
Result Snapshot
Revenue₹2,470 Cr₹1,422 Cr
PAT₹244 Cr₹267 Cr
EBITDA Margin19.7%23%
Sentimentbullishbullish
Key Quotes
We crossed a major milestone this year, surpassing $1 billion in revenue and having a growth of 16.6% year-on-year increase, exceeding the guidance row that we had given to you.
Our revenue from operations grew by 21%. While margins grew by 18%. Reflecting strong operating performance alongside continued investments to support future growth.